| >> |
Significantly reduce the toxicity
of the existing drugs (as in case of a few oncology drugs) |
| >> |
Significantly enhance the half-life of the
products in the blood, which means that the drug can be
effectively targeted. |
| >> |
Significantly improve the handling properties
of the drug, for example Lipid free Propofol. |
| >> |
The manufacturing process yields
a cost effective product, which effectively means that
the drug can be made available to the patients at a very
affordable cost. |
| >> |
The technologies developed are patentable
and would not infringe upon the existing technologies.
BSV has been cleared by PCT on 3 of its patent and another
7 applications are at various stages of filing and registration.
|
| Liposomal
Doxorubicin (non-pegylated) |
| >> |
Reduced cardiac toxicity when compared to
Doxorubicin (Adriamycin) |
| >> |
Longer half-life in the blood |
| >> |
Absence of hand foot syndrome
evident in pegylated Liposomal doxorubicin
(Doxil/Caelyx) |
| >> |
Ready to use formulation, as against three-step
preparation in the only other
non-pegylated Liposomal Doxorubicin approved for marketing.
(Myocet) |
| >> |
Patent Status: Provisional Patent
filed |
| Cisplatin
Emulsion |
| >> |
Reduced renal toxicity when compared to
Cisplatin |
| >> |
Tumour bearing studies onging (in US) |
| >> |
Patent Status
- Indian Patent Granted and PCT Applications filed in
various countries for entering National Phase filing |
| Amphotericin
B Emulsion |
| >> |
Reduced nephrotoxicity as compared to conventional
Amphotericin B |
| >> |
Enhanced uptake by RES system,
hence more effective in conditions like
Leishmaniasis |
| >> |
Lower therapy cost as compared
to Amphotericin B lipid complex &
Liposomal Amphotericin |
| Amphotericin
B Lipid Complex |
| >> |
Reduced nephro / hepato toxicity |
| >> |
Novel manufacturing process, obviating use
of solvents ( e.g. DMSO) |
| >> |
Patent Status – Indian
Patent Granted and the PCT office examination report to
be received |
| Propofol
Lipid Free |
| >> |
Enhanced Physical Stability |
| >> |
Clear solution - hence physical
inspection and sterile filtration possible |
| >> |
Ease of administration |
| >> |
No hypercholesteremia / hypertriglycridermia |
| >> |
No embolism |
| >> |
Reduced chances of contamination |
| >> |
Patent Status – Indian Patent
Granted and PCT Applications filed in various countries
for entering National Phase filing |
Sitemap